

Venetoclax in combination with HMAs both upfront and in the relapsed/refractory setting

Shyamala C. Navada, MD, MSCR

Assistant Professor

Mount Sinai School of Medicine

Department of Medicine

Division of Hematology/Oncology

New York, New York

There were many exciting abstracts at this year's ASH related to MDS. One drug that we've been using quite a bit in acute myeloid leukemia that's now being studied in MDS is venetoclax in combination with HMAs, both upfront and in the relapsed/refractory setting, and I think this combination would give us another option to use in higher-risk MDS patients. Another drug that I think has an exciting mechanism and the data looked promising was the anti-CD47 medication, also used in combination with HMAs. In addition, we know that p53 mutations are a poor prognostic factor in MDS patients and the combination of APR-246 with HMA also was an exciting part of this year's ASH publications as related to MDS.